يعرض 1 - 20 نتائج من 109 نتيجة بحث عن '"Puri, T"', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 1
    Academic Journal

    Relation: Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., de Braud, F., Solomon, B. J., Tan, D. S. -W., Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S. S., Puri, T., Bence Lin, A., Loong, H. & Besse, B. (2023). Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. JOURNAL OF CLINICAL ONCOLOGY, 41 (2), pp.385-+. https://doi.org/10.1200/JCO.22.00393.; http://hdl.handle.net/11343/320038

  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
  5. 5
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Conference
  11. 11
    Academic Journal

    المساهمون: The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, UK

    Relation: https://dx.doi.org/10.1093/oncolo/oyac264; Novello S, Califano R, Reinmuth N, Tamma A, Puri T. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape. ONCOLOGIST. 2023 MAY;28(5):402-13. PubMed PMID: WOS:001071170100018. English.; http://hdl.handle.net/10541/626673; Oncologist

  12. 12
  13. 13
  14. 14
  15. 15
    Conference
  16. 16
    Academic Journal
  17. 17
    Academic Journal

    المؤلفون: Puri, T

    المصدر: Indian Journal of Cancer ; volume 54, issue 1, page 83 ; ISSN 0019-509X

  18. 18
    Academic Journal

    المؤلفون: Puri, T

    المصدر: Indian Journal of Cancer ; volume 54, issue 2, page 394 ; ISSN 0019-509X

  19. 19
    Academic Journal
  20. 20
    Academic Journal

    مصطلحات موضوعية: ddc:no

    Relation: Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F. G. M., Solomon, B., Tan, D. Shao-Weng, Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S., Puri, T., Lin, A. B., Loong, H. H. F. and Besse, B. (2022). Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). Ann. Oncol., 33. S. S43 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041